Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder
Effect of Hydrocortisone Infusion on Hippocampal Glucose Metabolism, Neuropsychological Test Performance and Reexperiencing Symptoms in Patients With Post-Traumatic Stress Disorder (PTSD)
2 other identifiers
observational
93
1 country
1
Brief Summary
The purpose of this study is to determine whether people who develop Post-Traumatic Stress Disorder (PTSD) after a trauma have increased sensitivity to the effects of a stress hormone. Patients with PTSD have small hippocampal volume and deficits in hippocampal-mediated memory as compared to healthy people. However, it is unclear whether the smaller hippocampi are a consequence of PTSD or a risk factor for the development of PTSD. Some researchers believe that people who develop PTSD have an increase in cortisol levels during traumatic experiences and that this could be neurotoxic to the hippocampus. Others hypothesize that increased sensitivity of glucocorticoid receptors to cortisol, regardless of the cortisol levels, could lead to neurotoxic damage to the hippocampus. This study will compare responses to a stress hormone in patients with PTSD, participants who have experienced trauma but do not have PTSD, and healthy volunteers. Participants will be screened with a medical and psychiatric interview, physical examination, blood tests, electrocardiogram, and an emotional intelligence evaluation. Those eligible for the study will be asked to collect urine and saliva samples for 3 days. Participation will also include blood draws, a PET scan (brain imaging), an eye-blink test, neuropsychological testing, and other procedures. At another study visit, participants will undergo a magnetic resonance imaging (MRI) scan (brain imaging), questionnaires, and other procedures.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2002
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2002
CompletedFirst Submitted
Initial submission to the registry
June 6, 2002
CompletedFirst Posted
Study publicly available on registry
June 7, 2002
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2004
CompletedMarch 4, 2008
September 1, 2004
June 6, 2002
March 3, 2008
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- The study sample will consist of:
- Patients with a primary diagnosis of PTSD due to non-combat or combat related trauma according to DSM-IV.
- Subjects with non-combat related traumatic experiences without current PTSD and
- Healthy subjects without current or past history of psychiatric or major medical illness.
- All subjects will be between 18 and 60 years old.
- Male and female subjects will be included.
- All subjects must be able to give written informed consent prior to participation in this study.
- Patients with PTSD must score greater than or equal to 50 on Clinician-Administered PTSD Scale as a measure of PTSD symptom severity to be included in the study.
- Patients who are not currently on medications for PTSD. (Patients will not be discontinued from effective medication for purposes of the study).
- Patients who are nonresponders to other psychotropic drugs must have discontinued them for at least 2 weeks prior to the first PET scan. Medications will be discontinued under the supervision of the treating physician or a research psychiatrist listed in the protocol. (Nonresponders will be defined as subjects who continue to meet criteria for PTSD despite treatment with 30 mg equivalent of paroxetine for a minimum duration of six weeks).
You may not qualify if:
- Subjects with a clinically significant cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder.
- Patients who would be unable to comply with study procedures or assessments.
- Subjects with primary trauma related to motor vehicle accidents.
- Patients who meet DSM-IV criteria for alcohol and/or substance abuse or substance dependence within 6 months prior to screening.
- Patients who are currently on fluoxetine (Justification: Washout from fluoxetine could take up to six weeks).
- Patients who are currently at high risk for homicide or suicide.
- Subjects with a current or past history of other axis I disorders like schizophrenia, schizoaffective disorder, bipolar disorder or dementia will be excluded from the study. However, those with a comorbid history of other Axis 1 disorder like major depression, dysthymia or panic disorder will be included in the study. Justification: Approximately 70% of subjects with PTSD have comorbid depression and or alcohol abuse; reviewed in 134. Restricting the sample to PTSD patients without depression will not accurately reflect the biology of this disorder\].
- Subjects with a history of peptic ulcer disease will be excluded. (Justification: Those with a history of acid peptic disease requiring antacids in the past will be excluded, although it is unlikely that a single dose of intravenous hydrocortisone could precipitate bleeding due to gastritis or peptic ulcer disease).
- Women of childbearing potential who are not practicing a clinically accepted method of contraception or who have a positive pregnancy test or who are lactating.
- Subjects who donated a Red Cross unit of blood within 60 days prior to participation in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892, United States
Related Publications (3)
Bremner JD, Randall P, Scott TM, Capelli S, Delaney R, McCarthy G, Charney DS. Deficits in short-term memory in adult survivors of childhood abuse. Psychiatry Res. 1995 Nov 29;59(1-2):97-107. doi: 10.1016/0165-1781(95)02800-5.
PMID: 8771224BACKGROUNDBremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, Delaney RC, McCarthy G, Charney DS, Innis RB. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995 Jul;152(7):973-81. doi: 10.1176/ajp.152.7.973.
PMID: 7793467BACKGROUNDBremner JD, Randall P, Vermetten E, Staib L, Bronen RA, Mazure C, Capelli S, McCarthy G, Innis RB, Charney DS. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse--a preliminary report. Biol Psychiatry. 1997 Jan 1;41(1):23-32. doi: 10.1016/s0006-3223(96)00162-x.
PMID: 8988792BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- NIH
Study Record Dates
First Submitted
June 6, 2002
First Posted
June 7, 2002
Study Start
June 1, 2002
Study Completion
September 1, 2004
Last Updated
March 4, 2008
Record last verified: 2004-09